Symberix, Inc.
Durham, NC
- UEI
- HN72U2V5AKN7
- CAGE
- 6SXZ4
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 4819 Emperor Blvd #400, Durham, NC 27703, USA
- Website
- symberix.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Sbir phase i, topic 351: improving targeted cancer therapies by modulating the intestinal microbiome | National Cancer Institute (NIH) | $268,641 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Sanarentero LLC | Pearland, TX | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Biomesense Inc. | Chicago, IL | — |
| Envivo Bio Inc. | San Carlos, CA | — |
| Rise Therapeutics LLC | Rockville, MD | 325412 Pharmaceutical Preparation Manufacturing |
| Holobiome, Inc. | Boston, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Symberix, Inc. is an early stage spin out of the University of North Carolina at Chapel Hill that aims to improve human health by pioneering the development of symbiotic drugs that work by controlling bacteria without killing them. The company provides novel therapeutic approaches for the treatment of inflammatory bowel disease (IBD) and modulation of the gut microbiome through the development of small molecule drugs targeting gut dysbiosis.
Symberix, Inc. has received several federal grant awards from the National Institutes of Health (NIH) for its research and development efforts. In 2022, the company secured a $913,659 grant from the National Institute of Diabetes and Digestive and Kidney Diseases to develop small molecule drugs for the modulation of gut dysbiosis in patients with IBD. The project aims to confirm and extend pilot studies by evaluating the biological activity of two candidate small molecule drugs in an in vivo mouse model of ulcerative colitis and an ex vivo inhibition assay using IBD patient-derived stool samples. Additionally, Symberix received a $3,213,854 grant from the National Center for Advancing Translational Sciences in 2019 for developing novel inhibitors of the gut microbiome to modulate drug metabolism. The company also secured a $231,302 grant from the National Institute of Diabetes and Digestive and Kidney Diseases in 2019 for modulation of gut dysbiosis with Enterobacteriaceae-targeted antiproliferative agents to treat IBD.
Quick answers
Is Symberix, Inc. registered in SAM.gov?
Symberix, Inc.'s SAM.gov registration expired on July 19, 2026.
What is Symberix, Inc.'s most recent federal award?
Symberix, Inc.'s most recent federal grant award is Small molecule drugs targeting GUT dysbiosis to manage inflammatory bowel disease (R43DK131674), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on June 10, 2022.
On GovTribe
See Symberix, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors